Repligen (NASDAQ:RGEN) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Repligen (NASDAQ:RGEN) posted its quarterly earnings results on Tuesday. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09, Briefing.com reports. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The firm had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same period in the previous year, the business earned $0.23 earnings per share. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. Repligen updated its FY24 guidance to $1.50-1.58 EPS and its FY 2024 guidance to 1.500-1.580 EPS.

Repligen Stock Up 1.3 %

Shares of NASDAQ RGEN opened at $150.47 on Thursday. Repligen has a 1 year low of $113.50 and a 1 year high of $211.13. The firm has a market cap of $8.43 billion, a P/E ratio of -406.66, a price-to-earnings-growth ratio of 4.27 and a beta of 0.96. The firm’s 50 day moving average price is $141.59 and its 200 day moving average price is $144.78. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65.

Insider Transactions at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on RGEN. Wolfe Research started coverage on shares of Repligen in a research report on Thursday. They set a “peer perform” rating on the stock. Benchmark restated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Stephens reiterated an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research report on Tuesday, July 30th. JPMorgan Chase & Co. lifted their target price on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 31st. Finally, UBS Group lowered their price target on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $190.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.